Latest revenue
—
as of 2025-12-31
Latest net income
$-6.0M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think APUS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $18.9M
- Enterprise value
- $24.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.12×
- Dividend yield
- 0.0%
- 52-wk high
- $5.97
- 52-wk low
- $0.16
- Beta
- —
- Shares out
- 15.1M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business Overview On December 1, 2025, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (“APUS”, the “Company,” “we,” “us,” or “our”) entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”), with Apimeds Merger Sub, Inc., a Delaware corporation (“Merger Sub”), MindWave Innovations Inc, a Delaware corporation (“MindWave”), Lokahi Therapeutics, Inc., a Nevada corporation (“Bio Sub”), and Erik Emerson, solely in his capacity as representative for the Bio Business (the “Bio Business Representative”). The transactions contemplated by the Merger Agreement are referred to herein as the “Transactions” and the closing of the Transactions is referred to herein…
AI summary unavailable — showing raw filing excerpt
Generated from APUS's filing dated 2026-05-04
Key risks
Item 1A. Risk Factors As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this Item.
AI summary unavailable — showing raw filing excerpt
Generated from APUS's filing dated 2026-05-04
Profitability
Return on equity
-3.9%
103.8%Return on assets
-3.7%
100.0%Leverage
Debt / equity
0.07×
107.0%Debt / assets
6.6%
99.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-1.2M | -270.7% | — |
Q3 2025 2025-09-30 | — | — | $-1.8M | -435.7% | — |
Q2 2025 2025-06-30 | — | — | $-2.7M | -492.4% | — |
Q1 2025 2025-03-31 | — | — | $-402.4K | -35.7% | — |
Q4 2024 2024-12-31 | — | — | $-311.6K | — | — |
Q3 2024 2024-09-30 | — | — | $-332.5K | — | — |
Q2 2024 2024-06-30 | — | — | $-449.4K | — | — |
Q1 2024 2024-03-31 | — | — | $-296.5K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on APUS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns APUS
Institutional value
$712.4K
Total shares held
398.2K
Distinct holders
4
-3 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Hemenway Trust Co LLC | 274.0K | $490.3K | +0 (+0.0%) | No change |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 95.9K | $171.6K | — | New |
| 3 | VANGUARD FIDUCIARY TRUST CO | 24.0K | $43.0K | — | New |
| 4 | UBS Group AG | 4.2K | $7.5K | +3.6K (+619.4%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once APUS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.